Anti‐interleukin‐6 antibody clazakizumab in late antibody‐mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism

Targeting interleukin‐6 (IL‐6) is a promising strategy to counteract antibody‐mediated rejection (ABMR). In inflammatory states, IL‐6 antagonism was shown to modulate cytochrome P450 (CYP), but its impact on drug metabolism in ABMR treatment was not addressed so far. We report a sub‐study of a phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Mühlbacher, Jakob, Schörgenhofer, Christian, Doberer, Konstantin, Dürr, Michael, Budde, Klemens, Eskandary, Farsad, Mayer, Katharina A., Schranz, Sabine, Ely, Sarah, Reiter, Birgit, Chong, Edward, Adler, Scott H., Jilma, Bernd, Böhmig, Georg A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456861/
https://www.ncbi.nlm.nih.gov/pubmed/34153143
http://dx.doi.org/10.1111/tri.13954

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456861/
https://www.ncbi.nlm.nih.gov/pubmed/34153143
http://dx.doi.org/10.1111/tri.13954

Ejemplares similares